Psoriasis News and Research

Latest Psoriasis News and Research

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

VBL Therapeutics today announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis.

5 Jan 2010

Overview of Psoriasis

Psoriasis, a chronic disease that causes red, raised patches of skin, is increasingly seen as a systemic disease with links to arthritis and cardiovascular disease. The December issue of Mayo Clinic Women's HealthSource provides an overview of this sometimes embarrassing condition, what's known about it and how it's treated.

30 Dec 2009

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects. According to the paper, the researchers established the structural basis of PDE4 regulation through crystal structures of the PDE4 regulatory domain in contact with small molecules.

29 Dec 2009

Publication validates company's structure-based approach for addressing undruggable targets

28 Dec 2009

"Tan Tax" will hurt middle-class women and women-owned businesses

The proposed 10 percent federal tax on indoor tanning services, added to the latest U.S. Senate health care reform bill in a back-room deal over the weekend, will fall 40-50 percent short of delivering the revenue its proponents promised, according to the International Smart Tan Network (Smart Tan). The tax unfairly targets female consumers, who make up more than two-thirds of tanning clients, and would be detrimental to the thousands of women who own the majority of America's indoor tanning salons.

24 Dec 2009

Ligand Pharmaceuticals acquires Neurogen

Ligand Pharmaceuticals Incorporated announced today that it has completed the acquisition of Neurogen Corporation, following approval of the transaction by Neurogen stockholders earlier today. As a result, Ligand gains a fully funded partnership with Merck & Co., additional pipeline assets, drug discovery resources and additional cash balances.

23 Dec 2009

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine.

23 Dec 2009

Prasco Laboratories to market Stiefel Laboratories' Clobetasol Propionate Foam

Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.

22 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Ligand Pharmaceuticals, Neurogen revise merger agreement

Ligand Pharmaceuticals Incorporated and Neurogen Corporation announced today they have amended their merger agreement to increase the merger consideration payable

18 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

DNA reveals earliest proven case of leprosy, Turin Shroud not from Jesus-era Jerusalem

The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.

16 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Bio-Quant becomes wholly-owned subsidiary of NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing, Bio-Quant became a wholly-owned subsidiary of NexMed.

15 Dec 2009

Perrigo files Abbreviated New Drug Application for Clobex Spray

Perrigo Company today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray.

10 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Study: Besides nerves, skin has a unique sensory system

The human sensory experience is far more complex and nuanced than previously thought, according to a groundbreaking new study published in the December 15, 2009 issue of the journal Pain (http://www.painjournalonline.com/article/S0304-3959%2809%2900526-0/abstract).

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

1 Dec 2009

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

4SC AG, a drug discovery and development company, today announced that the European Patent Office has granted patent EP1392642, which covers its lead auto-immune compound 4SC-101.

1 Dec 2009

Psoriasis News and Research

Latest Psoriasis News and Research

Phase 2 study evaluating VBL Therapeutics' lead compound VB-201 initiated

Overview of Psoriasis

Emerald BioStructures engineers new allosteric small molecule modulators of the PDE4 enzyme

Publication validates company's structure-based approach for addressing undruggable targets

"Tan Tax" will hurt middle-class women and women-owned businesses

Ligand Pharmaceuticals acquires Neurogen

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Prasco Laboratories to market Stiefel Laboratories' Clobetasol Propionate Foam

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals, Neurogen revise merger agreement

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

DNA reveals earliest proven case of leprosy, Turin Shroud not from Jesus-era Jerusalem

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Bio-Quant becomes wholly-owned subsidiary of NexMed

Perrigo files Abbreviated New Drug Application for Clobex Spray

Specialty pharmaceutical market: Treatment patterns and product performance

Study: Besides nerves, skin has a unique sensory system

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in